Will giritinib be included in medical insurance in 2024?

Giritinib, as a targeted drug targeting FLT3 mutations, has shown significant therapeutic effects in the treatment of specific types of leukemia. However, the current medical insurance and purchase situation of gilitinib in China has caused problems for many patients.

First of all, regarding the issue of whether giritinib is included in medical insurance, according to the latest information, giritinib has been included in medical insurance in some regions, but the specific reimbursement conditions and proportions may vary from region to region. Generally speaking, giritinib is classified as a Class B drug under medical insurance, which means that patients can enjoy certain medical insurance reimbursement. However, the reimbursement rate is usually between 40% and 60%, and the patient may be required to receive treatment in a designated hospital and use giritinib as directed by the doctor.

However, although giritinib has been included in medical insurance in some areas, it is still not universally included in the medical insurance system nationwide. This has resulted in many patients facing difficulties in purchasing the drug. Since giritinib is an imported drug, its price is relatively high, which undoubtedly adds a huge financial burden to patients without medical insurance reimbursement.

In China, the price of gilitinib is about 25,000 yuan per box, and each box contains 42 tablets. Such prices are unaffordable for many patients. What troubles patients even more is that due to the limited domestic supply of gilitinib, even if patients are willing to pay a high price, it is often difficult to purchase this drug.

In order to solve this problem, some patients began to look for other purchasing channels, such as purchasing giritinib from India through purchasing agents. The price of giritinib in India is relatively low, about 4200 yuan per box, and each box contains 90 pills. However, there are certain risks in this purchasing method. For example, the authenticity, quality and safety of the drugs during transportation cannot be guaranteed.